Merck said it plans to make the drug available in the U.S. ahead of the upcoming RSV season. Enflonsia joins a growing arsenal of tools to prevent RSV in infants.

Merck plans to make ENFLONSIA available for ordering by physicians and health care administrators in July 2025, with shipments to be delivered before the start of the 2025-2026 RSV season.

HHS Secretary Robert F. Kennedy Jr. formally accepted recommendations that would require all vaccine manufacturers to ...

Merck, known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration has approved ENFLONSIA™ for the prevention of respiratory syncytial virus lower ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for the prevention ...

Merck plans to make ENFLONSIA available for ordering by physicians and health care administrators in July 2025, with shipments to be delivered before the start of the 2025-2026 RSV season.

Advisory Committee on Immunization Practices (ACIP) recommendation expands respiratory syncytial virus (RSV) prevention options: Merck’s Enflonsia is now recommended for infants under eight months of ...

“Enflonsia provides an important new preventive option to help protect healthy and at-risk infants born during or entering their first RSV season,” Dr. Dean Y. Li, president of Merck Research ...

Merck & Co., Inc. (NYSE:MRK) noted that ENFLONSIA is the first and only RSV preventive option administered to infants using the same dose regardless of weight, simplifying dosing logistics.

Merck plans to make Enflonsia available for physicians and healthcare administrators to order in July 2025. Shipments will be delivered before the start of the 2025-2026 RSV season.